Tag
Pharma / Healthcare
91 articles
Several Indian pharmaceutical and healthcare companies are navigating corporate governance and strategic shifts. Vaishali Pharma and Marksans Pharma are reappointing directors and approving related party transactions via postal ballots, while Parmax Pharma is increasing its authorized share capital and issuing shares through a preferential allotment. Additionally, Syngene International is undergoing a leadership transition with the resignation of its CEO, and Zydus Lifesciences is partnering with Apollo Hospitals to expand access to early cancer detection tests. These developments highlight ongoing corporate restructuring and strategic initiatives within the sector, potentially impacting investor sentiment and future growth prospects.
HC Cuttack Orders Jai Bharat Grievance Resolution
The High Court of Odisha at Cuttack disposed of writ petition W.P.(C) No.20064 of 2026 filed by M/s Jai Bharat Medicals, Titilagarh.
The court ordered District Medical Officer, Balangir, to address gr
Astec LifeSciences Postal Ballot Approves Director Appointments, RPTs
Astec LifeSciences shareholders approved all seven resolutions via postal ballot, including four director appointments.
Special resolutions passed for Arijit Mukherjee's executive directorship and Mat
Vaishali Pharma Postal Ballot Approves Director Appointments
Vaishali Pharma shareholders approved four special resolutions via postal ballot for director reappointments and remuneration increases.
All resolutions passed with over 99.85% approval from public no
Vimta Labs Pays ₹2 Per Share Dividend
Vimta Labs paid a final dividend of ₹2 per equity share for FY 2025-26 to eligible shareholders.
Dividend payment was made on July 4, 2026 following shareholder approval at the AGM.
The dividend was i
Samsrita Labs Board Approves Capital Reduction Scheme
Board approved Scheme of Capital Reduction to cancel 11.37 crore equity shares to set off accumulated losses.
Appointed Ravi Kanth Naga Pattabhi Chopperla as Additional Director (Non-Executive Profess
Supriya Lifescience GM Sales Under Judicial Custody
Supriya Lifescience discloses judicial custody of GM Sales Sreekant Sreedharan by Customs Department under NDPS Act.
The case involves procedural lapse in single export transaction, with custody grant
Fermenta Biotech Receives FSSAI Approval for VITADEE Green®
Fermenta Biotech received FSSAI approval for its plant-sourced Vitamin D3 product named VITADEE Green®.
The product is developed and manufactured in India, aligning with the Make in India initiative.
Rubicon Receives 2 US FDA Observations at Pithampur
Rubicon discloses US FDA inspection results for its Pithampur facility, conducted from June 29 to July 3, 2026.
The inspection concluded with a Form 483 containing 2 procedural observations, with no d
Syngene CEO Peter Bains Resigns Effective June 30
Syngene International MD & CEO Peter Bains resigns effective June 30, 2026, following leadership succession discussions.
The resignation was formally intimated to BSE and NSE under SEBI Listing Regula
Parmax Pharma EGM Approves Capital Hike and Preferential Issue
Parmax Pharma shareholders approved four resolutions at the July 2, 2026 EGM, including an increase in authorized share capital.
Shareholders passed a special resolution to issue 31,37,586 equity shar
Zydus Apollo Hospitals MoU Shield Cancer Test
Zydus Lifesciences signs MoU with Apollo Hospitals to expand access to Guardant Health's Shield™ Multi-Cancer Detection test in India.
The blood test screens for 10 common cancers in individuals aged
Marksans Pharma Sets 34th AGM, Final Dividend
Board approved 34th AGM on 27 August 2026 to be held via video conference.
Fixed 20 August 2026 as record date for final dividend of ₹0.90 per share.
Dividend payment scheduled for on or after 10 Sept
Sanofi India Wins ₹72.7 Lakh Tax Appeal
Sanofi India received a favorable order from the Income Tax Commissioner (Appeals) for AY 2019-20, dropping proceedings under Section 201.
The order deletes a tax demand of ₹72.71 lakh related to non-
Unichem Laboratories 63rd AGM Notice August 2026
Unichem Laboratories issues notice for its 63rd Annual General Meeting to be held virtually on 11th August 2026.
Seeks shareholder approval for re-appointment of MD & CEO Pabitrakumar Bhattacharyya wi
Laurus Labs Appoints Two Independent Directors at AGM
Laurus Labs appointed Dr. Shekhar Chintamani Mande and Ms. Sutapa Banerjee as Independent Directors effective July 2, 2026.
Both directors were approved for five-year terms at the company's 21st Annua
Dipna Pharmachem FY2026 Net Profit ₹263.19 Lakhs
Board approved audited financial results for Q4 and FY ended March 31, 2026, reporting a net profit of ₹263.19 lakhs for the full year.
Company operates in two reportable segments: Chemicals (revenue
Laurus Labs 21st AGM Approves Dividends, Director Appointments
Laurus Labs held its 21st AGM on July 2, 2026, passing all nine resolutions including adoption of FY26 financial statements.
Shareholders approved ratification of two interim dividends totaling ₹2.00
Parmax Pharma EGM Approves Capital Hike and Preferential Issues
Parmax Pharma shareholders approved four resolutions at an EGM held on July 2, 2026, including an increase in authorized share capital.
Shareholders passed a special resolution to issue 31,37,586 equi
Vaishali Pharma Board Approves ₹2Cr Authorised Capital Hike
• Board approved increase in authorised share capital from ₹27 crore to ₹29 crore, subject to shareholder approval.
• Draft postal ballot notice prepared for member approval of capital increase and MO
Parmax Pharma EGM Approves Capital Hike, Preferential Issue
Parmax Pharma held an EGM on July 2, 2026, approving four key resolutions including an increase in authorized share capital.
Shareholders approved a preferential issue of 31,37,586 equity shares to no
RPG Life Sciences 19th AGM Notice FY2025-26
RPG Life Sciences scheduled its 19th Annual General Meeting for July 23, 2026, at 3:00 PM IST via video conference.
The company notified shareholders without registered email addresses about online av
Anthem Biosciences Clarifies PAT Discrepancy and EPS Omission
Anthem Biosciences responds to NSE query on financial result discrepancies for FY26, confirming no PAT mismatch.
Company attributes non-disclosure of consolidated EPS in XBRL filing to an inadvertent
Novelix Pharmaceuticals EGM Approves Preferential Share Issue
Novelix Pharmaceuticals held an EGM on July 1, 2026, to vote on a special resolution for issuing equity shares on a preferential basis.
The resolution was passed with 99.9999% of votes cast (10,511,78
Senores Pharmaceuticals Postal Ballot for RPTs & IPO Variation
Senores Pharmaceuticals seeks shareholder approval via postal ballot for eight resolutions including material related party transactions.
Proposed RPTs with subsidiaries total ₹754 crore for FY27 and
Syngene International 33rd AGM Notice and Resolutions
Syngene International will hold its 33rd AGM virtually on July 29, 2026, to consider nine resolutions including financial statements adoption and dividend declaration.
Key resolutions include appointi
OneSource USFDA Inspection Concludes with One Observation
OneSource Specialty Pharma's sterile facility completed a USFDA cGMP inspection from June 22-30, 2026.
The inspection concluded with a single observation, requiring a comprehensive response from the c
MedPlus Subsidiary Receives 3-Day Drug License Suspension
MedPlus subsidiary Optival Health received a 3-day drug license suspension order for a Bangalore store from the Assistant Director, Drugs Control.
The order was received on July 1, 2026, citing violat
OneSource USFDA Inspection Concludes with One Observation
OneSource Specialty Pharma discloses completion of a routine USFDA cGMP inspection at its Bengaluru sterile facility.
The inspection, conducted from June 22-30, 2026, concluded with a single observati
Ajanta Pharma Paithan Facility Receives USFDA VAI Classification
Ajanta Pharma received a Voluntary Action Indicated (VAI) classification from the USFDA for its Paithan manufacturing facility.
The USFDA inspection was conducted from April 13 to April 21, 2026, and
Deccan Healthcare EGM for Three Director Appointments
Deccan Healthcare Limited convenes EGM on July 24, 2026 to regularize appointments of three independent directors.
The company seeks shareholder approval for five-year terms for Bhupendra Singh Katari
Deccan Healthcare Appoints Tushar Mandal as CFO
Deccan Healthcare appointed Mr. Tushar Mandal as Chief Financial Officer effective July 2, 2026.
The appointment was approved by the Board based on recommendations from Nomination and Audit Committees
Prevest DenPro FY26 Revenue Up 13.9% to ₹71.81 Cr
Prevest DenPro reported FY26 revenue growth of 13.9% to ₹71.81 crore, with exports rising 17.58% and domestic sales up 9%.
PAT increased 12.9% to ₹20.49 crore with strong margins: EBITDA at 38.6%, PBT
Aurobindo Pharma Completes Domestic Formulations Business Transfer
Aurobindo Pharma transfers its domestic branded generic formulations business to wholly-owned subsidiary Auropharm Limited.
The transfer was executed on a slump sale basis as a going concern, effectiv
Glenmark Advances Phase 3 Ovarian Cancer Trial
Glenmark Specialty S.A initiates multi-country Phase 3 trial for Trastuzumab rezetecan in platinum-resistant ovarian cancer following DCGI approval.
India is first market to enroll patients, with Aust
Lupin Receives FDA VAI Classification for Somerset Facility
Lupin received FDA Establishment Inspection Report with Voluntary Action Indicated classification for its Somerset, New Jersey manufacturing facility.
The satisfactory inspection outcome confirms regu
Dipna Pharmachem Reschedules Board Meeting to July 2
Dipna Pharmachem rescheduled its board meeting from July 1 to July 2, 2026 to discuss financial results.
The meeting will consider audited financial results for half year and year ended March 31, 2026
Lupin Subsidiary Increases MPPI Stake to 99.89%
Lupin's Dutch subsidiary Nanomi completed acquisition of 11.79 million MPPI shares from existing shareholders.
MPPI subsidiary also completed buyback of 61,118 shares with another 30,559 shares buybac
Wanbury FY26 Operational EBITDA Hits Record ₹108 Crore
• Wanbury reported FY26 revenue of ₹650.27 crore, up 8% YoY, with Operational EBITDA scaling 35% to a record ₹108 crore.
• The API business delivered ₹574 crore revenue with significant global market
Novelix Pharmaceuticals EGM Approves Preferential Share Issue
Novelix Pharmaceuticals held an EGM on July 1, 2026, to seek shareholder approval for issuing equity shares on a preferential basis.
The company conducted remote e-voting from June 28 to June 30, 2026
Sai Parenterals Schedules July 3 Analyst Meeting
Sai Parenterals Limited will participate in a group analyst/institutional investor meeting hosted by Nirmal Bang Securities on July 3, 2026.
The in-person meeting will be held in Mumbai from 4:30 PM t
Lupin Receives EMA Approval for NaMuscla Pediatric Expansion
Lupin announced EMA approval for NaMuscla expansion to pediatric patients aged 6-17 years with non-dystrophic myotonic disorders.
The approval includes two new dosage strengths (62 mg and 83 mg capsul
Sai Parenterals Subsidiary Secures AUD 202M Australia Contract
Sai Parenterals subsidiary Noumed Pharmaceuticals secured exclusive 7.5-year OTC medicine supply contract with Australia's leading pharmacy network.
Contract valued at AUD 202 million (INR 1300 crores
Senores Pharmaceuticals July 7 Analyst Meetings
Senores Pharmaceuticals intimates BSE and NSE of scheduled analyst and investor meetings pursuant to SEBI LODR Regulation 30(6).
Meetings are scheduled for July 7, 2026, at 10:00 AM IST at its plant i
SMS Pharmaceuticals Denies Pending Material Events
SMS Pharmaceuticals responds to BSE query on recent stock price and volume movement.
Company confirms full compliance with SEBI LODR Regulation 30 on material event disclosures.
Firm states it has no
GSK Pharma 101st AGM Approves All Resolutions
GSK Pharma's 101st AGM approved all six resolutions, including a dividend of ₹57 per share and director re-appointment.
The virtual meeting was held via video conferencing on June 30, 2026, with votin
Lyka Labs Promoter Kunal Gandhi Acquires 14,176 Shares
Lyka Labs promoter Kunal Gandhi acquired 14,176 equity shares via open market purchases on June 29, 2026.
The transaction value was ₹10,28,414.16, increasing his holding from 35,00,162 to 35,14,338 sh
Shelter Pharma FY26 Revenue Up 44% to ₹73.13 Cr
Shelter Pharma reported FY26 revenue of ₹73.13 Cr, up 44% YoY, with PAT at ₹9.03 Cr and an EBITDA margin of 17.39%.
The company is expanding with a new ₹12-15 Cr manufacturing facility near Ahmedabad,
TTK Healthcare FY26 Revenue Up 7% to ₹857 Crore
TTK Healthcare reported FY26 revenue growth of 7% to ₹857.28 crore but net profit declined 20% to ₹65.68 crore due to exceptional items including labour code provisions.
The Board recommended a final
Lyka Labs Promoters Acquire 56,000 Shares
Lyka Labs discloses promoter and promoter group open market share acquisitions totaling 56,000 equity shares.
Kunal Gandhi acquired 6,533 shares on June 25, 2026, increasing his holding to 3.5 million
Cipla 90th AGM Approves FY26 Results and Dividend
Cipla held its 90th Annual General Meeting via video conference on June 25, 2026, to present FY26 results and seek shareholder approvals.
The company reported its highest-ever annual revenue of ₹28,16
Anlon Healthcare Submits Q1 FY26 Results After Exchange Query
Anlon Healthcare responded to an NSE query regarding non-submission of its Q1 FY26 financial results by providing the required machine-readable format and covering letter.
The company reported a stand
Goldline Pharma Promoter Acquires 60,000 Shares
Goldline Pharmaceutical Ltd discloses promoter Swapan Khandelwal's open market purchase of 60,000 equity shares.
The acquisition represents 0.62% of total paid-up capital, increasing his holding from
Dishman Carbogen Amcis FY26 Results and ECB Approval
Dishman Carbogen Amcis reported consolidated net profit of ₹97.45 crore for FY26, a significant increase from ₹3.24 crore in FY25.
Board approved raising External Commercial Borrowings up to CHF 200 m
Astonea Labs FY26 Financial Results Clarification
Clarifies BSE query on FY26 financial results authorization, confirming Director Pardeep Dalal was duly authorized to sign.
Reports FY26 standalone revenue of ₹14,810.43 lakhs and net profit of ₹451.5
Johnson Pharmacare FY26 Loss ₹5573 Lakhs, Disclaimer Opinion
Johnson Pharmacare reported a standalone net loss of ₹5573.39 lakhs for FY26, with a disclaimer of opinion from auditors VRSK & Associates.
Auditors cited non-compliance with Ind AS, non-provision of
Parmax Pharma PAC Acquires 2.76% Stake Off-Market
Abhay Chinubhai Shah (PAC 8) acquired 249,394 equity shares (2.76%) of Parmax Pharma on June 18, 2026 via off-market transaction.
The acquisition was made at ₹35.00 per share from three individual sel
P&G Health FY26 Sales Up 16%, PAT Jumps 30%
P&G Health reported FY26 sales of ₹1400 crore, up 16% YoY, and profit after tax of ₹327 crore, up 30% YoY.
Management detailed three key innovations: Livogen Iron Gummies, Neurobion Nerve Pain Relief
Hester Biosciences FY26 Net Profit Surges 99% to ₹574.84M
Hester Biosciences reported 99% surge in consolidated net profit to ₹574.84 million for FY26, driven by operational efficiencies and strong poultry healthcare performance.
The company divested 43.81%
Hester Biosciences FY26 Net Profit Surges 99% to INR 575M
Hester Biosciences reported 99% YoY consolidated net profit growth to INR 574.84 million driven by favorable product mix and operational efficiencies.
The company divested 43.81% stake in Texas Lifesc
Amanta Healthcare Promoter Bhavesh Patel Buys 4,635 Shares
• Amanta Healthcare discloses promoter Bhavesh Patel's open-market purchase of 4,635 equity shares under SEBI Insider Trading Regulations.
• The transaction, executed on NSE on June 17, 2026, had a va
J.B. Chemicals 2026 AGM Voting Results Approval
J.B. Chemicals & Pharmaceuticals disclosed voting results from its 50th Annual General Meeting held on June 17, 2026.
All four proposed ordinary resolutions were passed, including adoption of FY26 fin
Parmax Pharma PAC Acquires 53,520 Shares
Rupa Sunil Shah acquired 53,520 equity shares in Parmax Pharma via off-market transaction on June 16, 2026.
Total shareholding of acquirer and PACs increased to 7,68,320 shares, representing 20.54% of
Amanta Healthcare Promoter Sells 5,000 Shares
Amanta Healthcare discloses a promoter group member's open-market sale of 5,000 equity shares.
The transaction, valued at ₹7,86,550, reduced the promoter's holding from 2.92% to 2.91%.
The disclosure
PGHH FY26 PAT Rises 19% on Flat Sales
Procter & Gamble Hygiene reported flat FY26 sales of ₹4300 crore but a 19% YoY PAT increase to ₹850 crore driven by productivity savings.
Management detailed its integrated growth strategy focusing on
Bharat Parenterals Promoter Buys 900 Shares
Bharat Parenterals Ltd filed a SEBI PIT Regulation 7(2) disclosure for a promoter's share acquisition.
Promoter entity Desai Shares and Stock Private Limited purchased 900 equity shares via on-market
Nutraplus India Q4 Net Loss ₹2.14 Lakhs
Board approved unaudited standalone financial results for Q4 and FY ended March 31, 2025, reporting continued losses.
Auditors issued qualified opinion due to material non-compliance with SEBI listing
Shelter Pharma H2 FY2026 Investor Call June 19
Shelter Pharma schedules H2 FY2026 investor call on June 19, 2026, to discuss audited financial results.
Managing Director Mustaqim Sabugar will lead the call to provide business and operational updat
Nutraplus India Q2 FY26 Results Delayed with Qualified Opinion
Nutraplus India's Board approved delayed Q2 FY26 results on October 25, 2025, with a net loss of ₹36.86 lakhs for the quarter.
Auditors issued a qualified review report citing non-compliance with list
Fredun Pharmaceuticals Q4 FY26 Net Profit Up 56.5%
Fredun Pharmaceuticals reported Q4 FY26 net profit of ₹11.07 crore, a 56.47% YoY growth, with total income up 27.27% to ₹213 crore.
The company announced new product launches in hormonal and anti-agin
Novartis India 26% Open Offer at ₹860.64/Share
Acquirers announce mandatory open offer for 26% of Novartis India shares at ₹860.64 per share.
Independent Directors Committee recommends the offer as fair per SEBI pricing regulations.
Tendering peri
Fredun Pharmaceuticals Q4 FY26 Earnings Call Recording
Fredun Pharmaceuticals disclosed audio recording of Q4 FY26 earnings conference call held on 10th June 2026.
Recording covers audited financial results for quarter and year ended 31st March 2026.
Audi
Sudarshan Pharma Promoter Releases 20 Lakh Share Pledge
Sudarshan Pharma promoter Hemal Mehta released a pledge on 20 lakh shares, representing 0.83% of total capital.
The release was executed on June 3, 2026, and disclosed to BSE under SEBI Takeover Regul
GSK India FY26 Net Profit Rises 12% to ₹1,036 Crore
GSK India reported 12% YoY net profit growth to ₹1,036 crore with revenue of ₹3,821 crore, recommending a final dividend of ₹57 per share.
The company maintained strong liquidity with ₹1,102 crore cas
Gufic Biosciences Q4 PAT Doubles to INR20.5 Crores
Gufic Biosciences reported Q4 FY26 revenue of INR252 crores, a 15% YoY increase, with PAT more than doubling to INR20.5 crores.
The Indore CMO facility reached 30% capacity utilization and EBITDA brea
ZIM Laboratories FY26 Revenue Flat at ₹374.4 Cr, Profit Drops 49%
ZIM Laboratories reported flat FY26 revenue of ₹374.4 crore but net profit declined 49% to ₹5.97 crore due to EU-GMP accreditation pause and Middle East geopolitical disruptions.
The company raised ₹3
ZIM Laboratories FY26 Financial Results and AGM Notice
ZIM Laboratories reported standalone revenue of ₹37,048 lakhs and net profit of ₹597 lakhs for FY26, a significant decrease from the previous year.
The company will hold its 42nd Annual General Meetin
Sigachi Industries Q4 FY26 Results and FY27 Guidance
Sigachi reported Q4 FY26 revenue of INR 121.89 crore with EBITDA of INR 15.4 crore and net profit of INR 7.6 crore.
Management provided FY27 revenue guidance of INR 650-675 crore with EBITDA margins o
Glenmark Q4 FY26 Earnings Call Transcript
Glenmark Pharmaceuticals submitted its Q4 FY26 earnings call transcript to stock exchanges as per SEBI LODR Regulation 30(6).
The earnings call was held on June 1, 2026, discussing financial results f
Sudarshan Pharma Audited FY2026 Results
Discloses audited standalone and consolidated financial results for the half-year and full year ended 31st March 2026, submitted to BSE in response to a query on discrepancies.
Reports standalone net
Ipca Labs Q4 FY26 EBITDA Margin Expands to 25.3%
Ipca Laboratories reported Q4 FY26 stand-alone EBITDA margin of 25.27%, a 408 basis point improvement year-over-year.
Consolidated revenue grew 8% to ₹9,646 crore in FY26 with domestic formulations gr
Anlon Healthcare Q4 FY26 Earnings Call Recording Available
Anlon Healthcare Limited made available the audio recording of its Q4 and FY26 earnings conference call held on June 3, 2026.
The disclosure is a regulatory compliance filing with BSE and NSE under SE
Cupid Promoter Aditya Halwasiya Acquires 2.1M Shares
Cupid Limited discloses promoter Aditya Halwasiya's acquisition of 2.1 million shares via open market purchase.
The transaction increases Halwasiya's direct holding to 33.29% and total promoter group
Cupid Promoter Aditya Halwasiya Acquires 2.6M Shares
Cupid Limited discloses promoter Aditya Kumar Halwasiya's acquisition of 26 lakh equity shares via open market purchases.
The transaction increases Halwasiya's direct holding from 32.94% to 33.08% and
Anupam Rasayan Open Offer for 26% Bliss GVS
Anupam Rasayan India Limited launched a mandatory open offer for 26% of Bliss GVS Pharma's expanded voting capital at ₹299 per share.
The offer, triggered by a Share Purchase Agreement to acquire a 43
Zydus Lifesciences Promoter Group Share Transmission
Zydus Lifesciences discloses transmission of 10,000 shares from deceased promoter Jasodaben Patel to Samar Patel.
The off-market transaction was executed on May 22, 2026 and intimated to the company o
Colinz Laboratories Promoter Vijaya Mani Sells 3.78 Lakh Shares
Colinz Laboratories discloses promoter Vijaya Mani's off-market sale of 378,000 equity shares on May 21, 2026.
Vijaya Mani's holding reduced from 1,248,500 shares (49.56%) to 870,500 shares (34.56%) p
Anuh Pharma Applies for 0.95% Promoter Group Reclassification
Anuh Pharma applied to stock exchanges to reclassify nine persons from Promoter Group to Public category under SEBI LODR Regulation 31A.
The reclassification request covers a total of 949,988 equity s
HCP Investments Sells 7.5% Stake in Ind-Swift Laboratories
HCP Investments disclosed disposal of 6.5M shares (7.5% stake) in Ind-Swift Laboratories via open market sales from April 13-17, 2026.
The transaction reduces HCP's holding from 8.649% to 1.149% of In
Beta Drugs Gains Regulatory Approvals in Azerbaijan, Philippines
Beta Drugs Limited's manufacturing facility received GMP inspection from Azerbaijan's Ministry of Health, with approval expected within 1-2 months.
The company obtained Certificates of Product Registr
Amanta Healthcare Clarifies Promoter Share Acquisition Discrepancy
Amanta Healthcare submits a clarification to BSE and NSE regarding a prior disclosure about promoter share acquisition.
The company corrects that only 13,300 shares were credited to promoter Bhavesh P
Novartis AG Sells 70.68% Stake, No Encumbrance
Novartis AG discloses no encumbrance on its 1.75 crore equity shares in Novartis India as of March 31, 2026.
Reiterates its agreement to sell its entire 70.68% stake to three acquirers, as per the Feb